Close Menu

NEW YORK — German molecular diagnostics firm Epigenomics on Thursday reported a 24 percent drop in its fiscal year 2020 revenues, mainly due to the impact of the COVID 19 pandemic, and said it is evaluating a potential sale of the company.

For the fiscal year ended Dec. 31, 2020, revenues for the Berlin-based firm dropped to €840,000 ($991,618) from €1.1 million in fiscal year 2019. Its product revenues declined 41 percent year over year to €584,000 from €988,000, and its license revenue declined 76 percent year over year to €33,000 from €137,000.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.